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Accurate and comprehensive assessment of platelet function across cohorts of donorsmay be
key tounderstanding the risk of thrombotic events associatedwith cardiovascular disease, and,
hence, to help personalize the application of antiplatelet drugs. However, platelet function tests
canbedifficult toperformandanalyze; theyalsocanbeunreliableoruninformativeandpoorly
standardized across studies. The Platelet Phenomic Analysis (PPAnalysis) assay and associated
open-source software platformwere developed in response to these challenges. PPAnalysis
utilizes preprepared freeze-driedmicrotiter plates to provide a detailed characterization of
plateletfunction.Theautomatedanalysisofthehigh-dimensionaldataenablestheidentification
of subpopulations of donorswith distinct platelet function phenotypes. Using this approach,we
identified that the sensitivity of a donor’s platelets to an agonist and their capacity to generate a
functional response are distinct independentmetrics of platelet reactivity. Hierarchical clus-
tering of thesemetrics identified 6 subgroupswith distinct platelet phenotypes within healthy
cohorts, indicating that platelet reactivity does notfit into the traditional simple categories of
“high” and “low” responders. These platelet phenotypeswere found to exist in 2 independent
cohorts of healthy donors andwere stable on recall. PPAnalysis is a powerful tool for stratifica-
tion of cohorts on the basis of platelet reactivity that will enable investigation of the causes and
consequences of differences in platelet function anddrive progress towardprecisionmedicine.
Introduction
Platelet function testing has been an important aspect of cardiovascular research, diagnostics, and investi-
gation of platelet biology since the invention of Born aggregometry in the 1960s.1 Platelets are central to the
pathology of cardiovascular disease (CVD), forming thrombi that occlude blood vessels and, hence, cause
major adverse cardiovascular events, such as myocardial infarction and ischemic stroke. Platelet function
tests measure the propensity of platelets to perform functions that are central to hemostasis and thrombosis,
such as the formation of aggregates, activation of integrin aIIbb3, or the secretion of dense and a granules.
These responses can be triggered by multiple stimuli, such as collagen, adenosine 59-diphosphate (ADP),
and thrombin to which platelets are exposed following vascular damage. There is a large degree of hetero-
geneity in the way in which platelets respond to these stimuli,2-4 but it is not fully understood why these dif-
ferences exist and whether they should be taken into account clinically. To understand the importance of
differences in platelet function, they must first be characterized and defined using comprehensive
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Figure 1. PPAnalysis workflow. A summary of PPAnalysis assay steps (AS) and data steps (DS). AS1, PPAnalysis plate is prepared, freeze-dried, and vacuum sealed. AS2,
Flow cytometry assay is performed using platelet-rich plasma. DS1, Concentration-response curves are fitted to data, and sensitivity and response capacity metrics are collected.
DS2, Data are summarized. DS3, Data are normalized, and barcodes are produced. Postanalysis hierarchical clustering and PCA are used to identify platelet function phenotypes.
The heat map depicts platelet metrics in the rows and individual donor responses in the columns (red indicates high; blue indicates low). Numbers above the heat map correspond
to the phenotypic groups identified by clustering.
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Figure 2. Characterization of platelet function with PPAnalysis. (A) Examples of concentration-response curves fitted to the data in DS1. Errors in the fitting process are
marked “Dirty” (eg, fibrinogen response to epinephrine). (B) Diagram depicting how the summary statistics sensitivity and capacity are extracted from concentration-response
curves fitted to data via the Hill function. (C) Examples of donor barcodes that capture a donor’s relative sensitivity and capacity and are produced in data step 3 (DS3). D035 is a
donor with high sensitivity to agonists but low capacity, whereas donor D006 has platelets with low sensitivity but a higher capacity, particularly P-selectin exposure in response to
CRP and TRAP-6. (D) Variability in measures of capacity and sensitivity for fibrinogen binding and P-selectin exposure in response to the 5 agonists. Outputs from DS1, DS2, and
DS3 for all donors are available in the code and data download.
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standardized tests. Only in this way can even basic questions regard-
ing the relative degree of heterogeneity in responses to different plate-
let agonists, such as the extent to which an individual might be
hyperresponsive to 1 agonist but hyporesponsive to another, be
answered.
We have developed and validated the Platelet Phenomic Analysis
(PPAnalysis) platform to simplify and standardize assessment of plate-
let function. The platform is designed to assess platelet function
across cohorts of donors recruited and assessed at multiple sites,
where reproducibility and consistency are paramount. As such, it uti-
lizes minimal specialist equipment, preprepared freeze-dried assay
plates, and bespoke software that eases the analysis of the high-
dimensional data. To aid implementation of the assay, step-by-step
instructions are included in supplemental Sections 1 through 3; all
data, software, and outputs are available for download.
Unlike other tests of platelet function, PPAnalysis utilizes multiple ago-
nists over a wide range of concentrations to pharmacologically charac-
terize the full range of platelet reactivity. To validate PPAnalysis we
tested 2 cohorts of healthy donors at separate study sites. We investi-
gated sources of variance within the data and, in particular, whether
sensitivity to an agonist and the magnitude of the functional response
to this agonist (capacity) were independentmetrics of platelet reactivity.
Using sensitivity and response capacity, we performed hierarchical
clustering to identify subpopulations with distinct platelet-reactivity phe-
notypes.Our aim is to provide a validated assay and analysis platform to
facilitate future studies of clinical and nonclinical cohorts that can eval-
uate the interplay among CVD, risk factors, and platelet function.
Methods and materials
Details about materials and reagents and step-by-step instructions for
PPAnalysis are included in supplemental Sections 1, 2, and 3, respec-
tively. Although we have endeavored to provide as much information
as possible to implement PPAnalysis, adaptation for alternative equip-
ment may be necessary; we welcome questions, comments, and sug-
gestions for improvement of these protocols.
Blood donation and cohorts
The study was carried out in accordance with the Declaration of Hel-
sinki. Recruitment of healthy fasted nonsmoking donors aged 30 to 65
years and free from drugs known to influence platelet function for
cohort 1 was approved by the University of Reading Research Ethics
Committee. Recruitment of nonfasted donors aged 18 to 75 years
(cohort 2) was approved by the Cambridge East Research Ethics
Committee.
Platelet function assay
The flow cytometry assay measured fluorescein isothiocyanate–
conjugated anti-fibrinogen antibody and PE-Cy5–conjugated anti–P-
selectin antibody binding following stimulation with ADP (0.03-30
mM), collagen-related peptide (CRP; 0.003-3 mg/mL), epinephrine
(0.1-30 mM), thrombin receptor activator peptide 6 (TRAP-6; 0.05-
15 mM), and U46619 (0.3-100 mM) using an Accuri C6 (BD, Win-
nersh, UK) for cohort 1 and a Beckman-Coulter EPICS Profile XL for
cohort 2, as described in supplemental Section 2.
Data analysis
Complete details about how to download the PPAnalysis software
and analyze the data are given in supplemental Section 2. PPAnalysis
software analyzes data in 3 steps (Figure 1):
 Data step 1 (DS1): processes the raw data, fitting
concentration-response curves. Data that fail to have a curve
fitted or are out of a predefined range are marked as “Dirty.”
A series of visualizations detailing the data, the fitted curve,
and any reasons for a Dirty status are provided together with
a summary file that details metrics for all donors.
 DS2: provides a range of summary visualizations that depict
population-level variation, correlations, assay consistency
and donors that lie out of normal population range (outliers).
 DS3: normalizesandscalesdata.Adonorbarcode is provided
that visually summarizes each donor’s response.
The availability of the software, data, and analysis outputs generated
from cohort 1 allows future users of the assay to trial and test the soft-
ware, which is modularized to allow easy adaptation and adjustments,
such as alternative plate designs (wellData.txt), filename formats (file-
nameSplit.R), or modification of rules for the identification of dirty data
(dirtyCheck.R).
Once processed, the variability in the data was investigated using
Principal Component Analysis (PCA) and then clustered using the
R hclust function (stats package) with distance measure Manhattan
and agglomeration method Ward.D2. The heat map visualizing the
clustering was plotted using the ComplexHeatmap function (Biocon-
ductor). The stability of donor and variable subgroups was tested
using PVclust, which utilizes a multiple bootstrap resampling algo-
rithm to calculate the approximately unbiased probability values for
cluster distinctiveness. All details about PCA and clustering are pro-
vided in R notebooks (NotebookPCA.Rmd and NotebookClusterAna-
lysis.Rmd, respectively); these offer a template that can be adapted
for users to carry out their own analysis.
Figure 3. Patterns of variability in cohort 1. (A) Correlation matrix summarizing patterns between the 12 measures of platelet function and the sensitivity and capacity of
fibrinogen and P-selectin to the agonists ADP, CRP, and TRAP-6. The area, shape, and color of the ellipses correspond to Spearman’s correlation coefficient. Colors indicate
Spearman’s correlation coefficient values ranging from 21 (dark red) to 11 (dark blue). The ellipse shape indicates the relative spread of data points and the slope of the
correlation, with a wider ellipse indicating a greater relative spread and a narrower ellipse indicating a lower spread (numerical values for Spearman correlation coefficients are
given in supplemental Figure S12. (B) Examples of concentration-response curves for 4 donors. The curves depicted in red and magenta have capacity and sensitivity that
correlate (high and low, respectively), whereas response curves in blue and gray do not follow this pattern and have high sensitivity but low capacity and vice versa. All curves are
for P-selectin in response to CRP. (C) Effects of platelet inhibitors (100 mM aspirin, 1 mM cangrelor, or both) on responses to ADP, CRP, and TRAP-6. Data are generated from
the responses of 10 blood donors. (D-E) Results of the PCA (scree plot is provided in supplemental Figure 18). The biplots show vectors representing each variable on a plane
where the angle between the vectors is informative; vectors closer together suggest dependence, whereas those that are orthogonal suggest a lack of independence in the
variables. (D) Biplot of PC1 and PC2. (E) PCA biplot of PC1 (x-axis) and PC3 (y-axis). In both biplots, colored arrows represent the contribution of each variable to the PC; arrows
representing measures of sensitivity are shown in red, and arrows representing measures of capacity shown in blue.
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Figure 4. Comparison of plate-based aggregarion (PBA) EC50 with capacity (upper panels) and sensitivity (lower panels).








PPAnalysis comprises a flow cytometry–based assay and bespoke
software that was developed to make data analysis simple, rapid,
and reproducible. The assay (Figure 1) uses assay plates containing
concentration ranges of ADP, CRP, epinephrine, TRAP-6, and
U46619, simultaneously measuring 2 aspects of platelet activation,
fibrinogen binding (a marker of aIIbb3 activation) and the exposure
of P-selectin on the platelet surface (a marker of a-granule secretion).
The plates can be easily reconfigured to include alternative types and
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Figure 5. Platelet function phenotypes. (A) Heat map resulting from hierarchical clustering of data from cohort 1. Each column represents a response variable, and each row
represents a donor. Red cells represent higher responses, and blue cells represent lower responses. (B) Rows are clustered into subgroups. Dendrograms, columns, and rows are
assessed by bootstrapping randomizations (Pvclust; n5 10000). Approximately unbiased. 90 indicates stable clusters. (C) Donors are placed on the plane of the first 2 PCs to
highlight subgroup characteristics. The x-axis goes from low responders on the left through to high responders on the right. The y-axis progresses from those donorswho have a higher
capacity than sensitivity at the bottom through to those with a higher sensitivity than capacity at the top. Subgroups 6 and 5 contain donors that are high responders. Subgroup 6 has
donors that have a higher sensitivity than capacity, whereas donors in subgroup 5 have a greater capacity of response than they are sensitive to agonists. Subgroups 4, 3, 2, and 1 are
lower responders. Group 3 contains general medium responders and group 2 contains lower responders, whereas group 1 contains donors with a greater sensitivity than capacity,
and group 4 are low responders with a greater capacity than sensitivity. Barcodes (displayed for donors D039 and D012) summarize individual donor characteristics.
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PPAnalysis: assessment of platelet function
PPAnalysis (Figure 1) was initially performed on platelet-rich plasma
from 50 fasted healthy donors (cohort 1). The software analyzes the
data in 3 simple steps (depicted in Figure 1 as DS1-3), taking 10
minutes to generate results for cohort 1 on a standard laptop com-
puter. The measurement of platelet responses evoked by such a
wide range of agonist concentrations allows the software to fit a Hill
curve to data, characterizing the concentration-response relationship
and enabling the extraction of multiple parameters that summarize
platelet reactivity (examples given in Figure 2A). Two key parameters
are the difference between baseline and maximal response and the
concentration needed to achieve half of this response (Figure 2B).
We refer to these properties as capacity of response and sensitivity,
to differentiate thesemetrics from efficacy and potency (50% effective
concentration [EC50]), which are commonly used to refer to the phar-
macological properties of agonists.
The software allows an unbiased, reproducible, and open assessment
























































































































































































Figure 6. Platelet function in response to a single concentration of agonists. Analysis of a single concentration of agonist selected retrospectively to provide optimal
capture of variation responses in 50 donors from cohort 1. (A) Variation in fibrinogen binding and P-selectin exposure responses. (B) PCA scree plot demonstrating percentage
variability captured by each PC; 85% variability is captured in just 2 PCs. (C) Biplot of first 2 PCs. (D) Heat map resulting from hierarchical clustering response to single
concentrations of agonist. Each column represents a response variable, and each row represents a donor. Red cells represent high responders, and blue cells represent low
responders. Donors are clustered into 3 groups: high, medium, and low responders. Annotations on the right side indicate the original clusters identified in the main text (Figure 4)
that use the sensitivity and capacity metrics, for comparison.



















































































   














































































































   





























































Figure 7. Patterns of variability in a second cohort of donors. (A) Scree plot demonstrating how much variability is captured by each PC. The first 3 PCs (PC1-3) capture
76% of the variability. (B) Biplot of PC1 and PC2. Measures of sensitivity (red) are distinct from capacity (blue). (C) Biplot of PC1 and PC3. (D) Donors from cohort 1 (prefix D)
and cohort 2 (prefix C) shown on the plane of the first 2 PCs. Color code as in Figure 5. (E) Cohort 1 donors at original assessment and at recall (denoted by suffix B) displayed on
the plane of the first 2 PCs.
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identify failures to fit concentration-response curves and extremes in
data. DS1 generated valid concentration-response curves for the
majority of donors (47 sufficient responses for fibrinogen; 50 sufficient
responses for P-selectin) in response to ADP, CRP, and TRAP-6, but
responses stimulated by epinephrine and U46619 were frequently
insufficient to enable curve fitting (epinephrine, 28 insufficient fibrino-
gen binding and 38 insufficient P-selectin exposure responses;
U44619, 12 insufficient fibrinogen binding and 6 insufficient
P-selectin exposure responses) (see supplemental Table 2 for
details).
DS2 generates publication-ready figures that summarize the cohort
response, describing variability, distributions, and correlations, and
aid quality assessment. These are provided in the data download;
an example plot of all metrics against collection date that enables qual-
ity control monitoring and assessment of “drift” caused by reagent
deterioration or “steps” caused by changes in reagent batches is
given in supplemental Figure 9, whereas Figure 2 (additional details
in supplemental Table 3) demonstrates the variability in capacity and
sensitivity.We observed that the capacity to generate P-selectin expo-
sure and fibrinogen binding is highest in response to the agonists
CRP (median, P-selectin, 14, 482; fibrinogen, 12, 614 mean fluores-
cence intensity [MFI]) and TRAP-6 (median P-selectin, 12, 239; fibrin-
ogen, 10, 688 MFI), whereas it is lower in response to ADP (median
P-selectin, 6, 721; fibrinogen 9, 951 MFI). Response capacity for epi-
nephrine, when present, was consistently low and skewed toward the
lower end of the range, with a large number of low responders.
Response capacity for U46619 was highly variable and could exceed
the capacity of ADP in some donors. The level of variability in sensitiv-
ity for fibrinogen binding and P-selectin exposure was different for
each of the agonists, with sensitivity to TRAP-6 displaying the least
variability [fibrinogen interquartile range, 26.07 to 25.93 log(M);
P-selectin interquartile range, 26.13 to 25.73 log(M)] and sensitivity
to CRP displaying the greatest [fibrinogen interquartile range, 27.52
to 27.12 log(g/L); P-selectin interquartile range, 27.53 to 27.17
log(g/L)]. Because of the high number of insufficient responses
recorded for the agonists U46619 and epinephrine, their metrics
were excluded from further analysis.
The third step in the analysis (DS3) normalizes and scales the data to
generate a graphical representation of a donor’s platelet functional
response that we call a barcode (Figure 2C). Each rectangle on the
barcode represents the relative sensitivity and capacity of a donor’s
platelets to the 3 agonists and 2 outputs. The width of the rectangle
represents the relative sensitivity of the response (a wide rectangle
depicts sensitive platelets), and the height of the rectangle represents
the relative capacity of the response.
The precision of the assay, when repeated on the same day, was
assessed by taking blood samples from 4 donors and repeating the
assay 6 times, on 2 different plate batches (3 tests on each plate
batch; supplemental Figure 10; supplemental Table 5). We also
assessed the precision of the assay when measurements were taken
on different days by taking blood samples from 5 donors on 4 sepa-
rate days within 1 month (supplemental Figure 11). Interquartile
ranges of these technical replicates were compared against those
measured across the entire population. We found that variability in
both groups of technical replicates for sensitivity were an order of
magnitude smaller than for the whole population (supplemental Fig-
ures 10 and 11). Variability in capacity measurements were greater
for both groups but small relative to interindividual variability.
In summary, PPAnalysis simplifies and makes easier a standardized
reproducible assessment of a high-dimensional description of platelet
function.
Sensitivity and capacity are distinct characteristics of
platelet function
Large-scale studies of platelet function often involve measuring
responses to 1 or relatively few3,4 concentrations of agonist and,
therefore, cannot fully differentiate sensitivity of platelets from their
capacity. In effect, they conflate sensitivity and capacity into a single
hybrid reactivity metric. Routine tests of platelet function using light
transmission aggregometry (LTA) commonly use a range of agonist
concentrations, but standardization is poor and analysis generally
does not routinely include estimation of parameters analogous to sen-
sitivity and capacity. Studies that use low-dimensional approaches
have classified donors and patients as having low or high platelet reac-
tivity. Characterization of the complete concentration-response curve
allowed us to identify that sensitivity to an agonist does not predict
capacity of response. Sensitivity and capacity for fibrinogen binding
or P-selectin exposure evoked by the agonist panel (Figure 3A) do
not correlate (jrj # 0.38; P . .01), indicating independence (supple-
mental Figures 12 and 13).
Figure 3B presents representative concentration-response curves
demonstrating all 4 possible combinations of high or low sensitivity
and capacity for P-selectin exposure evoked by CRP. Although the
measures of sensitivity and capacity did not correlate, there are indica-
tions of other patterns in responses. The sensitivity of fibrinogen bind-
ing and P-selectin exposure to individual agonists correlate (jrj .
0.91; P, .01) to a greater degree than does the capacity to generate
these responses (jrj , 0.76; P , .01). There are also correlations
between sensitivity to different agonists, with sensitivity to ADP and
TRAP-6 being particularly strongly correlated (fibrinogen, r 5 0.78;
P , .01; P-selectin, r 5 0.76; P , .01). Correlations between
responses mediated by ADP and other agonists may be due to the
release of ADP from platelets following agonist stimulation, which
stimulates P2Y receptors and contributes to activation. We investi-
gated the contribution of secreted ADP and thromboxane A2
(TxA2) by pretreating platelet-rich plasma with the P2Y12 antagonist
cangrelor and COX1 inhibitor aspirin (which prevents de novo synthe-
sis of TxA2) (Figure 3C). Fibrinogen binding capacity for CRP and
TRAP-6 was ablated in almost all cases following treatment with can-
grelor, indicating that integrin activation, and, hence, fibrinogen bind-
ing, is dependent on secreted ADP. P-selectin exposure capacity
and sensitivity were reduced by treatment with cangrelor (P , .05),
indicating a partial dependence on secreted ADP to trigger
a-granule release stimulated by CRP and TRAP-6. These results sug-
gest that PPAnalysis may be a useful tool for assessment of residual
platelet reactivity during treatment with P2Y12 antagonists. Estimates
of sensitivity and capacity were critical to identifying residual platelet
reactivity following treatment with cangrelor, because assessment
with only single concentrations of agonist failed to identify residual
P-selectin exposure following stimulation with CRP or TRAP-6 (sup-
plemental Figure 14). Dependence on TxA2 release was less pro-
nounced, with no significant effect on sensitivity and capacity for
CRP or TRAP-6 (P . .05).
Platelet count and mean platelet volume can influence functional
measurements, but we found that only ADP response metrics corre-
lated significantly with platelet count and mean platelet volume (P ,
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.05; supplemental Figures 15 and 16), and this accounts for a low pro-
portion of total variability (jrj , 0.44). We also investigated the influ-
ence of individual donor characteristics on functional measurements
and found that body mass index (BMI), age, and sex did not correlate
significantly within the cohort (supplemental Figure 17). Lack of signif-
icant correlations should be interpreted with caution as a result of the
limited age range (30-65 years) and low numbers of overweight and
obese individuals within this cohort of healthy donors.
We anticipated that some platelet function parameters might be highly
correlated, whereas others would be independent markers of platelet
function. We used PCA, a dimension-reduction technique that sum-
marizes the relationships between variables into “PCs” to distinguish
between parameters that are dependent and independent platelet
function metrics. The analysis revealed that the majority (85%; supple-
mental Figure 18) of variation within the entire data set was captured
by 3 PCs (Figure 3D-E). PC1 captures the overall response, grading
donors from generally low through to generally high responders. PC2
differentiates between themetrics sensitivity and capacity.When PC1
is plotted against PC2, measures of sensitivity and capacity are dis-
tinct (Figure 3D), confirming the results from the correlation matrix
that sensitivity and capacity are independent measures of platelet
function. PC3 (Figure 3E) highlights further structure within the
data, hinted at above, with the capacity metrics dividing into those
for P-selectin exposure and fibrinogen binding, whereas sensitivity
divides by agonist. This indicates that capacity could be inferred
from the response to any single agonist, suggesting that this metric
could be dependent upon common features, such as integrin expres-
sion levels, granule numbers, or expression of cellular signaling
machinery. However, the sensitivity is distinct for each agonist; there-
fore, it is necessary to test a range of agonists.
We compared PPAnalysis outputs with results from theOptimul plate-
based LTA test performed on the same samples to provide a compar-
ison with an established platelet function test. Optimul is sensitive to
mild and severe platelet function disorders.5 We found that sensitivity
measured using PPAnalysis correlated with the EC50 identified by
LTA for each agonist, indicating that this metric corresponds well
with results from a standard method (Figure 4). However, capacity
did not correlate with EC50, suggesting that this metric corresponds
to a feature of platelet function that is not identified by standard
methods.
Identification of platelet phenotypes
To discover whether distinctive platelet function phenotypes exist in
healthy populations, the data from cohort 1 were clustered using an
agglomerative hierarchical algorithm that groups individuals together
on the basis of similarity. The columns of the resulting heat map (Fig-
ure 5A) represent the 12 variables describing platelet function, and
the rows represent the individual donor responses. The dendrogram
above the heat map divides the metrics of sensitivity and capacity. It
then divides capacity into the 2 functional measures of P-selectin
exposure and fibrinogen binding and then by agonist. However, sen-
sitivity is divided first by agonist and then by functional measure. Taken
together, this indicates that sensitivity and capacity are distinct inde-
pendent measures of platelet function. Capacity to generate functional
responses of fibrinogen binding and P-selectin exposure are indepen-
dent of each other, but the sensitivity to each agonist in generating
these responses is similar (eg, the sensitivity to ADP is similar when
measuring fibrinogen binding or P-selectin exposure). However, the
sensitivity to each agonist is distinct (eg, an individual that is highly
sensitivity to ADP may not be sensitive to CRP).
The rows in the heat map depict individual donor responses that have
been clustered into stable subgroups with similar patterns of sensitiv-
ity and capacity (demonstrated in the dendrogram; Figure 5B); colors
indicate subgroups (also placed to the left of the heat map). To visu-
alize the separation of donors into distinct phenotypic groups, donors
were placed on the plane of the first 2 PCs (PC1 and PC2) identified
in Figure 3 (Figure 5C). The x-axis (PC1) distinguishes between low
and high responders, whereas the y-axis (PC2) separates donors
with a greater capacity than sensitivity (at the bottom) from those
with a greater sensitivity than capacity (top). The algorithm identifies
3 groups with matching levels of high (group 6), medium (group 3),
and low (group 2) sensitivity and capacity, which could fit into the tra-
ditional paradigm of low, medium, and high platelet reactivity. How-
ever, 3 more complex groups are also identified; groups with high
capacity and medium sensitivity (group 5), medium capacity and
low sensitivity (group 4), and low capacity and high sensitivity (group
1). By clustering the data we revealed groups of donors with distinct
platelet phenotypes that are more complex than defining donors as
simply low or high responders.
To understand differences from previous studies that used single con-
centrations of an agonist to assess platelet function, the data were
reduced to an optimal single concentration of each agonist (Figure
6). PCA highlights the reduced dimensionality of these data, needing
just 2 PCs to capture most (87%) of the variability: the first accounts
for the majority of this (68%) and grades donors from low to high res-
ponders. The remaining structure in the data differentiates by agonist
in a similar manner to sensitivity (Figure 3E). Clustering allowed
donors to be separated into 3 subgroups of low, medium, and high
responders. These groups were compared with the donor subgroups
identified by PPAnalysis (side annotation on heat map; Figure 6).
There is general agreement in the ability of the 2 approaches to grade
donors from low through to high responders; however, donors pre-
dominantly identified by PPAnalysis as having a high capacity and
lower sensitivity (PPAnalysis Group 5) are misclassified by single con-
centration analysis, with 6 of the 8 donors shifted from high respond-
ers to medium responders.
These results demonstrate that PPAnalysis facilitates stratification of
donors using sensitivity and capacity to identify multiple distinct phe-
notypes rather than just “low” and “high” reactivity groups.
Platelet phenotypes are replicated in a second cohort
of donors
To evaluate whether the platelet function phenotypes identified are
present in other healthy cohorts, a second cohort of donors (cohort
2) was recruited at a second study center. Recruitment criteria for
cohort 2 were broadened to include nonfasted donors with a greater
age range (18-75 years); despite these changes being likely to
increase variation, PCA of the data revealed similar patterns of variabil-
ity (Figure 7) to cohort 1. The majority of the variability was still cap-
tured in 3 PCs that again differentiate donors by low to high
responses, followed by sensitivity and capacity.
Combining the data generated for both cohorts demonstrated that
donors from cohort 2 can be placed into the subgroups identified pre-
viously (Figure 7D). Donors from cohort 2 populated all 6 platelet func-
tion subgroups, including groupswith high capacity and low sensitivity
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and vice versa. This validates the platelet phenotypes identified previ-
ously, while also demonstrating that PPAnalysis allows cohorts
recruited at different sites to be combined.
Platelet phenotypes are stable over time
High variability in platelet function between individuals2-4 reflects gen-
uine heterogeneity. Previous studies of variation in platelet function
have demonstrated consistency in their responses over periods rang-
ing from weeks to months, with greater changes in function occurring
over longer periods.6,7 To assess the short-term stability of platelet
phenotypes identified by PPAnalysis, 5 donors (D1-5) were assessed
on 4 occasions over a period of 1month. To assess long-term stability,
14 donors from cohort 1 were recalled and retested 18 to 24 months
after the original assessment.
Results from the 5 donors recruited to assess short-term variability
were combined with results from cohort 1 and assigned phenotypes;
thiswas repeated for eachdayof reassessment.All 5donorswerecon-
sistently classified into the same phenotypic group at each of the 4
assessments (supplemental Figure 19). Results from the donors
recalled to assess long-term stability were combined with the data
from the original assessment before reclustering. Sixty-eight percent
(9/14) of the recalled donors were classified into the same groups
as during the original visit (Figure 7E). Twenty-one percent of the
donors shifted to the nearest neighboring groups and retained the gen-
eral classification of high or low responders. Only 14% of the donors
(2/14) moved to entirely distinct groups: 1 from the medium-
responder group to the high-responder group and 1 from the
high-responder group to the low-responder group.
Taken together, these results indicate that PPAnalysis is sufficiently
accurate and phenotypic groups are sufficiently stable over short
time periods for donors to be assigned to the same group when
retested. In the longer term, platelet function phenotypes are stable
for the majority of those retested up to 2 years later. However,
changes in phenotype appear to occur in a minority of patients, pos-
sibly as a result of modification of environmental factors that influence
platelet function, such as BMI, cholesterol, and alcohol consumption.
Discussion
Precision medicine has not yet delivered benefits for CVD treatment,
with improvements needed in patient phenotyping and integration of
omics data to achieve progress.8 Despite clear heterogeneity in the
responses to treatments for patients with CVD, a successful strategy
for stratification of patients within high- and moderate-risk groups has
not been established. The challenge is to bring about a reduction in
adverse cardiovascular events without an increased risk for hemor-
rhage. Donor phenotyping is needed to achieve this for patients using
current antiplatelet drugs. Stratification using risk factors, such as age,
obesity, and sex, appear to be insufficient, particularly in the context of
primary prevention with aspirin.9 We developed PPAnalysis on the
basis of the hypothesis that systematic measurement of platelet func-
tion biomarkers would reveal subgroups with distinct phenotypes that
might be used to personalize treatment.
PPAnalysis measures concentration-dependent responses to ago-
nists of the key targets of current and potential antiplatelet therapies.
Efficacy and safety of antiplatelet drugs that target the platelet ADP
receptor P2Y12 are known to vary, and underlying platelet hyperreac-
tivity has been implicated as a significant source of variability in the
pharmacodynamics of clopidogrel.10 In this preliminary study, we
found that sensitivity to ADP was highly variable, with the least sensi-
tive responders requiring a nearly 10-fold greater concentration of
ADP to stimulate half-maximal activation compared with the most sen-
sitive responders (Figure 2; supplemental Table 3). However, the
range of responses to the GPVI receptor agonist CRP were even
greater, with a difference of 1.5 orders of magnitude between the
most and least sensitive responders. This might have major implica-
tions for proposed new therapies, such as the anti-GPVI Fab fragment
ACT017,11 suggesting that baseline platelet reactivity might have an
even greater confounding role in pharmacodynamics. Sensitivity to the
PAR1 agonist TRAP-6 demonstrated the least variability; although a
similar range of responses to ADP was observed, the variation was
the lowest among the agonists tested (supplemental Table 3). This
corresponds with the low variability in the pharmacodynamics of the
PAR1 antagonist vorapaxar in phase 1 studies.12
In addition to sensitivity, PPAnalysis measures response capacity,
which quantifies the magnitude of the functional outputs of integrin
aIIbb3 activation and a-granule secretion. The conformational change
that enables integrin aIIbb3 to bind fibrinogen is a critical step in
thrombosis and hemostasis. Drugs targeting this receptor, such as
abciximab, eptifibatide, and tirofiban, are potent antithrombotic agents;
however, they have limited clinical utility as a result of their negative
impact on hemostasis.13 We found that levels of fibrinogen binding
to the activated integrin following stimulationwith ADPwere highly var-
iable. Response capacity for TRAP-6 andCRPwere similar and higher
than for ADP, corresponding with ADP being a weak agonist.14 How-
ever, blockade of the ADP receptor P2Y12 with cangrelor demon-
strated that fibrinogen binding response capacities to TRAP-6 and
CRP were themselves dependent upon ADP released from platelet
dense granules (Figure 3E). This is likely due to the strong activation
of phosphatidylinositol 3-kinase stimulated by the P2Y12 receptor,
which is required for activation of the integrin-activating small GTPase
Rap1.15 Therefore, PPAnalysis measures the ability to secrete ADP in
response to TRAP-6 and CRP as part of the response capacity.
A systematic approach to characterization of platelet function using
the 2 separate metrics of sensitivity and capacity has not been under-
taken previously, and we found that these metrics are independent,
reflecting distinct aspects of platelet function (Figure 3). This new
approach suggests that the concept of platelet reactivity, which has
been a useful tool in understanding resistance to antiplatelet therapy,
might be an oversimplification. High platelet reactivity in patients fitted
with drug-eluting stents is associated with an increased risk for myo-
cardial infarction,16 yet increased clopidogrel dosing due to high
on-treatment platelet reactivity does not offer any benefit.17-19 Using
PPAnalysis, we demonstrated the existence of platelet responses
that are characterized by high sensitivity and low capacity, or vice
versa, which is not compatible with the concept of simply high and
low reactivity. This indicates the existence of individuals with both
high sensitivity and capacity who might be more resistant to antiplate-
let medication, as well as individuals with low sensitivity and capacity
who might be more prone to adverse bleeding events.
To enable the results of PPAnalysis to be used as a practical research
and decision-making tool, we incorporated techniques for dimensional
reduction into the freely available software. Utilizing PCA and cluster-
ing, we identified 6 subgroups with distinct platelet-reactivity profiles
(platelet function phenotypes; Figure 5). Identification of these 6 dis-
tinct phenotypes suggests that the concept of “low” and “high”
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platelet reactivity could be another oversimplification. In the context of
secondary prevention of CVD, point-of-care tests may successfully
identify patients who are at increased risk; however, results from differ-
ent tests rarely agree with each other,20 suggesting that they measure
different aspects of platelet reactivity that are more accurately delin-
eated by PPAnalysis.
Studies utilizing flow cytometry to characterize platelet function have
been especially valuable in determining the genetic basis for popula-
tion variability.3,4,6,21 However, these studies often rely on low-
dimensional data sets, including platelet responses to only 1 or 2 con-
centrations of agonist. We replicated this approach by retrospectively
analyzing responses to only a single concentration of each agonist.
This approach yielded weaker discriminatory power compared with
analysis that incorporated sensitivity and capacity, enabling identifica-
tion of only 3 distinct clusters of low, medium, and high responders.
Large-scale studies of hereditary platelet bleeding disorders fre-
quently fail to identify a cause.22 The enhanced capability of PPAnal-
ysis to distinguish platelet function phenotypes may help to identify
genetic variants that determine variation in platelet function. PPAnaly-
sis can be paired with microtiter plate-based aggregometry for studies
in which responses to U46619, epinephrine, ristocetin, or arachidonic
acid are important.
We found that PPAnalysis phenotypes were highly stable over short
periods of time. Over longer periods of up to 24 months, the majority
of phenotypes remain stable upon retesting. This is in keeping with
studies that have indicated that platelet responses remain consistent
over time.2,3,7 The existence of stable platelet function phenotypes
agrees with studies that have identified heritable factors as key deter-
minants of platelet function.4,23 However, although heritable factors
are dominant in determining platelet reactivity, nonheritable and envi-
ronmental factors, such as age, BMI, triglyceride and cholesterol
levels, and menopause, are also known to affect platelet reactivity.24
This is in line with the fact that a minority of donors within the cohort
changed phenotype when retested over a longer time frame.
In conclusion, PPAnalysis provides a foundation for studies investigat-
ing associations between platelet function and disease, genetics, and
therapeutic interventions. Our ongoing studies will investigate associ-
ations between the phenotypic groups identified using PPAnalysis
and the risk of bleeding and thrombosis in patients. Our hope is
that open access to the PPAnalysis assay method and software will
facilitate standardization of this aspect of cardiovascular research
and enhance the scope of collaborative research and the potential
for meta-analysis, as well as facilitate multicenter and longitudinal
studies.
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